Betrixaban: A Novel Oral Anticoagulant With a New Niche
| Autor: | Grazia Murphy, Sadaf Chaudry, Yasmin Grace, Rita Chamoun |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
business.industry MEDLINE Pharmaceutical Science Atrial fibrillation Review Article 030204 cardiovascular system & hematology medicine.disease law.invention Clinical trial 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Pharmacokinetics chemistry Randomized controlled trial law Internal medicine Betrixaban medicine Oral anticoagulant cardiovascular diseases 030212 general & internal medicine business Venous thromboembolism |
| Zdroj: | The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians. 34(3) |
| ISSN: | 8755-1225 |
| Popis: | Objective: To evaluate the efficacy, safety, and clinical implication of betrixaban for prophylaxis of venous thromboembolism (VTE) in patients with acute medical illness. Data Sources: A search for clinical trials was performed from January 2006 to January 2017 in English language using Clinicaltrials.gov and PubMed/MEDLINE. The following search terms were used: betrixaban, pharmacokinetics, pharmacology, and drug safety. Study Selection: The following limits were used to access the clinical trials: controlled clinical trial, randomized clinical trial, clinical trial, clinical trial phase II, and clinical trial phase III. The search was narrowed to include only humans. Data Extraction: The search criteria resulted in 6 clinical trials assessing the safety and efficacy of betrixaban. Additionally, references from publications assessing the safety and efficacy of betrixaban in atrial fibrillation, treatment and prevention of VTE, and extended duration VTE prophylaxis were assessed. Data Synthesis: Prior to 2017, no anticoagulant therapy had been approved for extended VTE prophylaxis in acutely ill medical patients. Betrixaban is the first direct oral anticoagulant approved for VTE prophylaxis in adult, acutely ill patients at risk for thromboembolisms. Based on the APEX trial, betrixaban 80 mg administered daily for 35 to 42 days was compared to enoxaparin administered daily for 6 to 14 days. In 7441 patients, fewer VTEs were seen in the betrixaban compared to enoxaparin with no significant difference in adverse reactions. Conclusion: Based on clinical trials, betrixaban appears to be safe and effective in preventing VTE in acutely ill patients who are at risk of developing VTE. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|